Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 77

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Uveal melanoma

Recruiting

Study of ipilimumab, nivolumab and melphalan combination therapy with hepatic perfusion in patients with advanced uveal melanoma that has spread to other organs

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Leiden University Medical Center

Pancreatic carcinoma

Recruiting

Study on the Use of Hyperpolarized Pyruvate for MRI Scans in Patients with Pancreatic Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pyruvic Acid
  • Sponsor:Aarhus University

Neoplasm

Recruiting

Study of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Centre Leon Berard

B-cell lymphoma+1

Recruiting

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:LYSARC

Colorectal cancer metastatic

Recruiting

Study of Dendritic Cell Vaccine and Aldesleukin Treatment in Patients After Surgery for Stage IV Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Colorectal cancer metastatic

Recruiting

Study of Valproic Acid, Panitumumab, and Irinotecan for Patients with Metastatic Colorectal Cancer with RAS/BRAF Wild-Type

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm

Recruiting

Study of ORIC-114 Alone or with Chemotherapy for Patients with Advanced Solid Tumors with EGFR or HER2 Alterations

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ORIC-114
  • Sponsor:ORIC Pharmaceuticals Inc.

Chronic myeloid leukaemia

Recruiting

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier De Versailles

Chronic lymphocytic leukaemia+1

Recruiting

Study of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Chronic myeloid leukaemia

Recruiting

Study on Stopping Dasatinib in Patients with Chronic Myeloid Leukemia After a Previous Attempt to Stop Treatment

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Region Uppsala

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.